Double‐blind multicenter comparison of fluvoxamine versus sertraline in the treatment of depressed outpatients

Depression

Volumn 3, Issue 4, 1995, Pages 163-169

  Nemeroff, Charles B ^a   Ninan, Philip T ^a   Ballenger, James ^b   Lydiard, R Bruce ^b   Feighner, John ^c   Patterson, William M ^d   Greist, John H ^e  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c Feighner Research Institute   (United States)

^d Birmingham Radiological Group PC   (United States)

^e Dean Foundation   (United States)

Author keywords

depression; double blind; fluvoxamine; sertraline; sexual dysfunction; tolerability

Indexed keywords

FLUVOXAMINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; SEXUAL DYSFUNCTION; SOMNOLENCE;

EID: 0029553059     PISSN: 10626417     EISSN: 15227162     Source Type: Journal    
DOI: 10.1002/depr.3050030402     Document Type: Article

References (18)

1. Are patients who are intolerant to one SSRI intolerant to another?
2. The Hopkins Symptom Checklist (HSCL): A self‐report symptom inventory
3. Paroxetine, sertraline, and fluvoxamine: New selective serotonin reuptake inhibitors
4. Sexual dysfunction, Part I: Classification, etiology, and pathogenesis
5. The assessment of anxiety states by rating
6. Development of a rating scale for primary depressive illness
7. Pharmacotherapy of anxiety and depression: Rationale and study design
8. The modified scale for suicidal ideation: Reliability and validity
9. Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive‐compulsive disorder
10. Replication of factors of psychopathology in interview, ward behavior and self‐report ratings of hospitalized de‐pressives
11. Focus on fluvoxamine. A serotonin reuptake inhibitor for major depression and obsessive‐compulsive disorder
12. The potential benefits of serotonin receptor‐specific agents
13. Clinical pharmacokinetics of selective serotonin reuptake inhibitors
14. Fluvoxamine. A review of its safety profile in world‐wide studies
15. Fluvoxamine: An updated review of its pharmacology, and therapeutic use in depressive illness